Tango Therapeutics reports Q4 2024 net loss of $37.7M; cash runway into 3Q 2026

Tango Therapeutics, Inc.

2024-FY EPS reported -$1.19 revenue$42,069,000

Net loss of $37.7M for Q4 2024 ($0.35 per share) vs $30.8M loss in Q4 2023; full year net loss $130.3M ($1.19 per share).
Cash and marketable securities $257.9M as of Dec 31, 2024; expected to fund operations into 3Q 2026.
TNG462 granted FDA Orphan Drug Designation for pancreatic cancer; Phase 1/2 data update expected in 2025.
IND for TNG456 cleared; Phase 1/2 enrollment expected 1H 2025; clinical collaboration with Lilly for abemaciclib combination.
TNG260 proof-of-mechanism established; dose expansion ongoing in lung cancer; clinical update expected 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.